"Biomarkers, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS.
Descriptor ID |
D014408
|
MeSH Number(s) |
D23.101.140
|
Concept/Terms |
Biomarkers, Tumor- Biomarkers, Tumor
- Tumor Biomarkers
- Markers, Biological Tumor
- Tumor Markers, Biological
- Markers, Tumor Metabolite
- Tumor Metabolite Markers
- Metabolite Markers, Tumor
- Marker, Tumor Metabolite
- Metabolite Marker, Tumor
- Tumor Metabolite Marker
- Tumor Markers, Biologic
- Biologic Tumor Markers
- Markers, Biologic Tumor
- Marker, Biologic Tumor
- Biologic Tumor Marker
- Tumor Marker, Biologic
- Biochemical Tumor Markers
- Markers, Biochemical Tumor
- Marker, Biochemical Tumor
- Biochemical Tumor Marker
- Tumor Marker, Biochemical
- Tumor Markers, Biochemical
- Carcinogen Markers
- Markers, Carcinogen
- Markers, Neoplasm Metabolite
- Neoplasm Metabolite Markers
- Marker, Neoplasm Metabolite
- Metabolite Marker, Neoplasm
- Neoplasm Metabolite Marker
- Metabolite Markers, Neoplasm
- Biological Tumor Markers
- Biological Tumor Marker
- Tumor Marker, Biological
- Marker, Biological Tumor
Markers, Tumor- Markers, Tumor
- Tumor Markers
- Biomarkers, Cancer
- Cancer Biomarkers
|
Below are MeSH descriptors whose meaning is more general than "Biomarkers, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Tumor".
This graph shows the total number of publications written about "Biomarkers, Tumor" by people in this website by year, and whether "Biomarkers, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 15 | 7 | 22 |
1996 | 11 | 16 | 27 |
1997 | 15 | 15 | 30 |
1998 | 24 | 29 | 53 |
1999 | 21 | 28 | 49 |
2000 | 21 | 35 | 56 |
2001 | 42 | 31 | 73 |
2002 | 40 | 47 | 87 |
2003 | 52 | 63 | 115 |
2004 | 68 | 57 | 125 |
2005 | 78 | 80 | 158 |
2006 | 81 | 78 | 159 |
2007 | 92 | 68 | 160 |
2008 | 95 | 71 | 166 |
2009 | 102 | 88 | 190 |
2010 | 86 | 119 | 205 |
2011 | 116 | 116 | 232 |
2012 | 114 | 116 | 230 |
2013 | 130 | 96 | 226 |
2014 | 148 | 102 | 250 |
2015 | 148 | 102 | 250 |
2016 | 155 | 139 | 294 |
2017 | 151 | 131 | 282 |
2018 | 113 | 131 | 244 |
2019 | 141 | 125 | 266 |
2020 | 132 | 128 | 260 |
2021 | 110 | 119 | 229 |
2022 | 7 | 100 | 107 |
2023 | 5 | 76 | 81 |
2024 | 68 | 104 | 172 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.
-
Primary gastric T-cell lymphoma presenting with perforation: a case report and review of the literature. J Hematop. 2024 Dec 30; 18(1):2.
-
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial. Signal Transduct Target Ther. 2024 Dec 24; 9(1):369.
-
Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids-The CASPAR Study. Clin Cancer Res. 2024 Dec 16; 30(24):5559-5567.
-
Real-World and Clinical Trial Validation of a Deep Learning Radiomic Biomarker for PD-(L)1 Immune Checkpoint Inhibitor Response in Advanced Non-Small Cell Lung Cancer. JCO Clin Cancer Inform. 2024 Dec; 8:e2400133.
-
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics. Eur J Cancer. 2025 Jan 17; 215:115169.
-
Molecular Pathway and Immune Profile Analysis of IPMN-Derived Versus PanIN-Derived Pancreatic Ductal Adenocarcinomas. Int J Mol Sci. 2024 Dec 07; 25(23).
-
Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response. JCO Precis Oncol. 2024 Dec; 8:e2400288.
-
Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas. Neuro Oncol. 2024 Dec 05; 26(12):2239-2255.
-
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study. Clin Cancer Res. 2024 Dec 02; 30(23):5304-5313.
-
Plasma DNA Methylation-Based Biomarkers for MPNST Detection in Patients With Neurofibromatosis Type 1. Mol Carcinog. 2025 Jan; 64(1):44-56.